Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 3
2012 3
2013 3
2014 3
2015 7
2016 7
2017 6
2018 6
2020 4
2021 7
2022 8
2023 4
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Grade 2 Nausea, CTCAE"
Page 1
Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study.
Gazzah A, Bedard PL, Hierro C, Kang YK, Abdul Razak A, Ryu MH, Demers B, Fagniez N, Henry C, Hospitel M, Soria JC, Tabernero J. Gazzah A, et al. Ann Oncol. 2022 Apr;33(4):416-425. doi: 10.1016/j.annonc.2021.12.012. Epub 2022 Jan 10. Ann Oncol. 2022. PMID: 35026412 Free article. Clinical Trial.
The primary endpoint was the incidence of dose-limiting toxicities (DLTs) during the first two cycles, graded using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 criteria. RESULTS: Thirty-one patients received tusamitamab …
The primary endpoint was the incidence of dose-limiting toxicities (DLTs) during the first two cycles, graded using National Cancer I …
[(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.
Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG, Sandhu S. Hofman MS, et al. Lancet Oncol. 2018 Jun;19(6):825-833. doi: 10.1016/S1470-2045(18)30198-0. Epub 2018 May 8. Lancet Oncol. 2018. PMID: 29752180 Clinical Trial.
The most common toxic effects related to [(177)Lu]-PSMA-617 were grade 1 dry mouth recorded in 26 (87%) patients, grade 1 and 2 transient nausea in 15 (50%), and G1-2 fatigue in 15 (50%). Grade 3 or 4 thrombocytopenia possibly attributed …
The most common toxic effects related to [(177)Lu]-PSMA-617 were grade 1 dry mouth recorded in 26 (87%) patients, grade 1 and …
A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors.
Metaxas Y, Kahatt C, Alfaro V, Fudio S, Zeaiter A, Plummer R, Sessa C, Von Moos R, Forster M, Stathis A. Metaxas Y, et al. Invest New Drugs. 2022 Feb;40(1):91-98. doi: 10.1007/s10637-021-01142-1. Epub 2021 Aug 28. Invest New Drugs. 2022. PMID: 34453241 Clinical Trial.
Patients in Group A additionally received orally 125 mg aprepitant one hour before cisplatin on Day 1 and 80 mg on Days 2 and 3. Toxicity was graded according to the NCI-CTCAE v.4. Results RD for Group A was cisplatin 60 mg/m(2) plus lurbinectedin 1.1 …
Patients in Group A additionally received orally 125 mg aprepitant one hour before cisplatin on Day 1 and 80 mg on Days 2 and 3. Toxi …
Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature.
Chow R, Herrstedt J, Aapro M, Chiu L, Lam H, Prsic E, Lock M, DeAngelis C, Navari RM. Chow R, et al. Support Care Cancer. 2021 Jul;29(7):3439-3459. doi: 10.1007/s00520-020-05935-7. Epub 2021 Jan 13. Support Care Cancer. 2021. PMID: 33442782 Free PMC article.
The primary efficacy endpoints were the rate of complete response, in the acute (0-24 h post-chemotherapy), delayed (24-120 h post-chemotherapy), and overall (0-120 h post-chemotherapy) phases. The secondary efficacy endpoints were the rates of no nausea and no emesis, for …
The primary efficacy endpoints were the rate of complete response, in the acute (0-24 h post-chemotherapy), delayed (24-120 h post-chemother …
Age as a potential predictor of acute side effects during chemoradiotherapy in primary cervical cancer patients.
Holmqvist A, Lindahl G, Mikivier R, Uppungunduri S. Holmqvist A, et al. BMC Cancer. 2022 Apr 7;22(1):371. doi: 10.1186/s12885-022-09480-w. BMC Cancer. 2022. PMID: 35392858 Free PMC article.

RESULTS: Patients 52 years had a significantly higher frequency of nausea/vomiting and increased grade 3 toxicity during CRT compared to younger patients (p < 0.001, p = 0.001). Toxicity grade 3 of nausea/vomiting was associated with increased frequ

…
RESULTS: Patients 52 years had a significantly higher frequency of nausea/vomiting and increased grade 3 toxicity during CRT c …
Hypnosis on patients treated with adjuvant chemotherapy for breast cancer: A feasibility study.
Fabbro M, Jacot W, Jarlier M, Guiu S, D'Hondt V, Pouderoux S, Champoiral P, Janiszewski C, Nicklès I. Fabbro M, et al. Cancer Rep (Hoboken). 2023 Jan;6(1):e1732. doi: 10.1002/cnr2.1732. Epub 2022 Oct 27. Cancer Rep (Hoboken). 2023. PMID: 36302744 Free PMC article.
The overall compliance with self-hypnosis was 68.6% (95% CI: 50.7%-83.2%), meaning that more than two thirds of patients performed at least four sessions of self-hypnosis. According to NCI-CTCAE, Grade 2 nausea and vomiting was observed in 45.7% …
The overall compliance with self-hypnosis was 68.6% (95% CI: 50.7%-83.2%), meaning that more than two thirds of patients performed at …
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients.
Sundlöv A, Gleisner KS, Tennvall J, Ljungberg M, Warfvinge CF, Holgersson K, Hallqvist A, Bernhardt P, Svensson J. Sundlöv A, et al. Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3830-3840. doi: 10.1007/s00259-022-05786-w. Epub 2022 Apr 22. Eur J Nucl Med Mol Imaging. 2022. PMID: 35451612 Free PMC article. Clinical Trial.

The overall toxicity was mild, and the most common events were grade 1-2 anemia, thrombocytopenia, fatigue, nausea, and diarrhea. Grade 3-4 toxicity occurred in < 10% of patients and was mostly hematological, with no grade 3-4 renal toxicity.

…
The overall toxicity was mild, and the most common events were grade 1-2 anemia, thrombocytopenia, fatigue, nausea, and …
Ganglioside-monosialic acid (GM1) for prevention of chemotherapy-induced peripheral neuropathy: a meta-analysis with trial sequential analysis.
Wu S, Bai X, Guo C, Huang Z, Ouyang H, Huang J, Zeng W. Wu S, et al. BMC Cancer. 2021 Nov 2;21(1):1173. doi: 10.1186/s12885-021-08884-4. BMC Cancer. 2021. PMID: 34727879 Free PMC article.
Subgroup analyses showed that GM1 could not reduce the risk of CTCAE grade 2 CIPN (OR 0.63, 95% CI 0.35-1.13) and neurotoxicity criteria of Debiopharm (DEB-NTC) grade 2 CIPN (OR 0.25, 95% CI 0.01-7.10) in oxaliplatin-treated patients, despite th …
Subgroup analyses showed that GM1 could not reduce the risk of CTCAE grade 2 CIPN (OR 0.63, 95% CI 0.35-1.13) and neuro …
Stomach Dose-Volume Predicts Acute Gastrointestinal Toxicity in Chemoradiotherapy for Locally Advanced Pancreatic Cancer.
Holyoake DLP, Warren DR, Hurt C, Aznar M, Partridge M, Mukherjee S, Hawkins MA. Holyoake DLP, et al. Clin Oncol (R Coll Radiol). 2018 Jul;30(7):418-426. doi: 10.1016/j.clon.2018.02.067. Epub 2018 Mar 28. Clin Oncol (R Coll Radiol). 2018. PMID: 29602584 Clinical Trial.
The outcome measures used were Common Terminology Criteria of Adverse Events (CTCAE) grade and risk of CTCAE grade 2 acute upper gastrointestinal toxicity (anorexia, pain, nausea and/or vomiting). The risk of CTCAE grade …
The outcome measures used were Common Terminology Criteria of Adverse Events (CTCAE) grade and risk of CTCAE grade …
Digestive toxicities after palliative three-dimensional conformal radiation therapy (3D-CRT) for cervico-thoracic spinal metastases.
Peyraga G, Caron D, Lizee T, Metayer Y, Septans AL, Pointreau Y, Denis F, Ganem G, Lafond C, Roche S, Dupuis O. Peyraga G, et al. Support Care Cancer. 2018 Jun;26(6):1897-1903. doi: 10.1007/s00520-017-4001-4. Epub 2017 Dec 23. Support Care Cancer. 2018. PMID: 29275524
The median overall time of treatment was 13 days [3-33]. Forty patients (31.3%) suffered from grade 2 of "esophagitis" (35 grade 2 (27.4%) and 5 grade 3 (3.9%)). Eight patients (6.3%) suffered from grade 2 of "nausea and/or …
The median overall time of treatment was 13 days [3-33]. Forty patients (31.3%) suffered from grade 2 of "esophagitis" (35 …
54 results